FGFR1 and prostate carcinoma: In addition, potential targetable amplifications were detected, i.e. high level amplifications of ERBB2 [45–47] (colorectal carcinoma, salivary duct carcinoma, prostate cancer, ovarian cancer), MET [48, 49] (lung cancer, esophageal carcinoma), and FGFR1 [50] (lung cancer, colorectal carcinoma).